Three PI3K inhibitors, Idelalisib, Copanlisib, Duvelisib, are currently FDA approved for treating relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or indolent lymphoma2–4. The gene discussed is PIK3CG; the disease is B-cell chronic lymphocytic leukemia.